LOGIN  |  REGISTER
Compass Therapeutics

Valeo Pharma Announces Listing To The Toronto Stock Exchange

March 28, 2022 | Last Trade: C$0.05 0.00 0.00

The Company's shares and warrants to start trading on March 29th, 2022

Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has received final approval for the listing of its common shares and warrants on the Toronto Stock Exchange ("TSX").

Valeo Pharma Logo (CNW Group/Valeo Pharma Inc.)

The Company's common shares and warrants will commence trading on the TSX effective as of market open on Tuesday March 29, 2022 (the "Effective Date"), and will continue to trade under the current symbols of "VPH", "VPH.WT" and "VPH.WT.A. The Company's commons shares and warrants will concurrently be de-listed from the CSE as of the Effective Date.

"Listing on the TSX, Canada's senior stock exchange, is an important step supporting our development as a leading Canadian pharmaceutical company", said Steve Saviuk, CEO. "The TSX platform  enhances Valeo's exposure to a broader investor audience which will benefit all our shareholders".

About Valeo Pharma

Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respirology, Neurodegenerative Diseases, Oncology and other specialty products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.

Forward Looking Statements

This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page